Trivector Biomed LLP introduces ZyMōt Sperm Separation Device – A New Age ‘Lab-On-Chip’ IVF Solution in India

National, October 28, 2020: Trivector Biomed LLP, a pioneer in the IVF space, has further strengthened its name with the launch of a world-class product from ZyMōt Fertility. Since the outbreak of COVID-19 pandemic, IVF treatments has witnessed a decrease in percentage as many doctors have been skeptical in terms of people visiting clinics and hospitals for treatments due to spread of COVID-19 infections. With the complexity involved in treatments such as this, it becomes imperative to have an environment that assures utmost safety & healthiest approach to the procedure, which is made possible through ZyMōt Fertility devices. By introducing this device to the Indian IVF sector, Trivector Biomed LLP is optimistic to streamline new age IVF solutions in the Indian healthcare landscape.

ZyMōt Fertility (promoted by DxNow, USA), a well-known international brand operating in the IVF space has found a better way to select the healthiest sperm – naturally, effectively, and efficiently, with the product ZyMōt Sperm Separation Devices. Based on a philosophy that ‘The future of Fertility is Simplicity’, these separation devices are innovative lab-on-chip tools that efficiently isolate the healthiest, rapidly progressive sperm using microfluidics and micro-filtration technology, to help achieve the best possible outcomes, especially in these COVID times. With the male-factor being a cause of infertility in about 50 % infertile population, such an innovative solution which eliminates multiple potentially damaging steps  of sperm handling in the lab, comes as a much needed medical intervention in the IVF domain.

US-FDA approved – ZyMōt Multi Sperm Separation Device is the first-of-its-kind device that makes it simpler for the professionals and patients. The sperm preparation (or sperm-wash) methods like swim-up and density gradient need sperms to go through processes like pipetting, mixing and centrifugation, which induces reactive oxidative stress (ROS) on the sperm. Oxidative stress is detrimental as it leads to  DNA fragmentation of the genetic material of the sperm which results in poor pregnancy rates.  These ZyMōt devices are designed and developed to aid reproductive medicine professionals in the natural separation of the healthiest and best-performing sperm (the Winners) for use in assisted reproductive technology (ART) procedures – without sperm-damaging  procedures like centrifugation.

Dilip Patil, Managing Director, Trivector Biomed LLP said, “Our company has been successfully operating and reinventing solutions in the IVF industry for the past 25 years, we have seen the growth and challenges faced by our industry associates working towards educating the people. IVF centres have gained wider acceptance since the early nineties and the pregnancy rates increased to about 10-15% through IVF treatments. According to ICMR estimates, currently in India more than 2000 IVF clinics are treating about 300,000 patients every year with an average pregnancy rate of about 35-40%.”

He further added, “Now, with this COVID-19 times, the industry is facing a challenge of reduced footfalls for the fear of infection. Even though all the patients before enrolling for IVF treatment are pre-tested for COVID-19 and all recommended protocols are being followed by clinics and the patients. However, the clinics are wary of handling the biological material, especially the potentially infectious reproductive tissues. Thus, we are promoting this unique product of ZyMōt Fertility that uses a natural approach to separate the healthiest sperm and eliminate multiple steps required to handle and process the sperm in the lab.”

These devices have been tested and are well-accepted internationally, including  some of the Indian Hospitals such as Hegde Hospital, Hyderabad, Jaslok Hospital, Mumbai etc, where they have reported significant reduction in DNA fragmentation and improvement in pregnancy rates. The findings of improvement in success rate after using ZyMōt Devices have been presented and published during annual meetings of ESHRE (European Society of Human Reproduction and Embryology) and ASRM (American Society of Reproductive Medicine).

Corporate Comm India (CCI Newswire)